OPHTHOCHLOR Drug Patent Profile

Which patents cover Ophthochlor, and what generic alternatives are available?

Ophthochlor is a drug marketed by Parkedale and is included in one NDA.

The generic ingredient in OPHTHOCHLOR is chloramphenicol. There are fourteen drug master file entries for this compound. Additional details are available on the chloramphenicol profile page.

Summary for OPHTHOCHLOR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,187
DailyMed Link:	OPHTHOCHLOR at DailyMed

US Patents and Regulatory Information for OPHTHOCHLOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parkedale	OPHTHOCHLOR	chloramphenicol	SOLUTION/DROPS;OPHTHALMIC	061220-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 5, 2026

Ophthochlor market dynamics and financial trajectory: pricing, demand drivers, competition, and patent-driven risk

Ophthochlor (active ingredient: ophthochlor, ophthalmic antiseptic compound) has limited public, transaction-level financial visibility in the open record compared with major marketed ophthalmic brands. Market dynamics therefore hinge on (1) local authorizations and distribution reach by geography, (2) formulary and channel position versus substituted ophthalmic antiseptics, (3) tariff and reimbursement mechanics where applicable, and (4) exclusivity duration tied to the underlying patent and regulatory file. Financial trajectory is typically characterized by early adoption in targeted ophthalmology settings, then plateauing under multi-source substitution pressure once barriers fall.

What is determinative for the financial path is not a single catalyst but a set of coupled constraints: patent expiration timing (and any Orange Book or equivalent regulatory listings where available), regulatory transferability (label compatibility across strengths/dosage forms), and the speed of generic/authorized copy entry. Without a confirmed, verifiable product dossier, holder, NDC/listing, and patent registry record for Ophthochlor, it is not possible to produce a defensible market sizing curve, revenue CAGR, or exclusivity-by-exclusivity financial model.

What is Ophthochlor and what indications shape demand?

Ophthochlor is an ophthalmic antiseptic used in eye care contexts that may include prophylaxis/antisepsis in ocular procedures, treatment of ocular surface bacterial contamination, or supportive indications depending on the licensed label in each jurisdiction.

Which clinical positioning drives purchasing behavior?

Demand in ophthalmic antiseptics typically comes from:

• Hospital ophthalmology and procedural workflows (peri-procedural antisepsis).
• Outpatient clinics that stock or dispense antiseptic drops/solutions.
• Procurement schedules tied to formulary inclusion, infection control protocols, and tender cycles.

What label scope changes revenue shape?

Two label variables materially affect financial trajectory:

• Indication breadth: broader therapeutic/setting use expands addressable demand.
• Wettability and dosing regimen on-label: more convenient dosing often increases adoption and reduces switching friction.

How do market dynamics work for ophthalmic antiseptics versus branded substitutes?

Ophthalmic antiseptics typically compete against:

• Other antiseptic eye drops (e.g., povidone-iodine variants, chlorhexidine-based products, or alternate actives where allowed).
• Combination products that bundle antisepsis with supportive anti-inflammatory or antimicrobial coverage.
• Off-label use of broader-spectrum ophthalmic antimicrobials, depending on local prescribing norms.

Price competition and channel mechanics

Ophthalmic antiseptics face:

• Short tender windows in public systems.
• High switching sensitivity once a multi-source supply exists.
• Strong private-label and authorized-generic risks in open markets.

Substitution risk by dosage form

Revenue risk concentrates if Ophthochlor is:

• Sold in a dosage form that is easy to copy (solution drops).
• Not protected by formulation-specific patents beyond the API and basic claims.

When does Ophthochlor lose exclusivity and how does that affect entry risk?

Financial inflection in ophthalmic products usually tracks exclusivity cliffs: when patent coverage narrows or regulatory data exclusivity ends, generic or authorized copies accelerate.

What exclusivity mechanisms typically matter in this category?

Common exclusivity drivers include:

• Patent term end for composition of matter (API).
• Patent term end for formulation and container closure systems.
• Regulatory exclusivity tied to first approval or new clinical investigations.
• Litigation settlement triggers that govern launch timing.

What generic entry risks exist?

Generic launch risk is highest when:

• Claims are narrow to a single manufacturing approach or specific concentration.
• No blocking patents cover the commercial formulation.
• The product’s clinical label is not tied to method-of-use protections.

Which patents protect Ophthochlor and how strong is the estate?

A complete, litigation-relevant patent assessment requires a verified patent list for Ophthochlor, including numbers, assignees, jurisdictions, and claim scope across API, formulation, and method-of-use. Public sources are not reliably sufficient in the open record under the single name “Ophthochlor” to produce a litigation-grade estate map.

Patent estate components that determine financial resilience

For ophthalmic antiseptics, the most value-relevant layers are:

• Composition of matter patents for the active pharmaceutical ingredient (API).
• Formulation patents for stabilizers, preservatives, pH targets, buffers, osmolarity, and viscosity modifiers.
• Manufacturing process patents for critical steps (sterile filtration, irradiation targets, container fill parameters).
• Use patents that tie antiseptic use to specific clinical workflows.

What is the Orange Book status of Ophthochlor and which paragraphs IV filings matter?

A defensible Orange Book status and Paragraph IV analysis requires confirmed FDA listing identifiers (proprietary name, active ingredient description, dosage form, strength) and the corresponding listed patents for that specific product.

Why Orange Book details change launch timelines

Paragraph IV challenges create:

• An automatic 30-month stay if a first filer is successful in the procedural pathway.
• A potential 180-day exclusivity grant for the first applicant, if conditions are met.
• Settlement-driven launch dates that can move revenue by multiple years.

Without a confirmed Orange Book listing, it is not possible to state:

• Whether Ophthochlor is listed.
• Which patents are listed against which product.
• Whether any Paragraph IV certifications exist.

What formulations are protected by Ophthochlor patents?

Ophthalmic antiseptics often have multiple commercial presentations (strengths, fill volumes, bottle/closure configurations, preservatives). Financial outcomes depend on whether patents cover:

• The full commercial range of strengths.
• The specific container-closure system that maintains sterility and stability.
• Any pH or tonicity ranges that drive tolerability.

Typical formulation patent claim patterns

Common claim anchors include:

• Defined pH ranges.
• Defined concentrations of stabilizers/preservatives.
• Defined buffers or isotonicity agents.
• Defined viscosity or surfactant content.

How does Ophthochlor compare with competing ophthalmic antiseptics on price and switching?

Competitive dynamics are usually determined by:

• Net price after tenders and rebates.
• Availability and delivery reliability (in hospitals, supply continuity matters).
• Tolerability and perceived clinical effectiveness in routine practice.

What drives switching in ophthalmic antiseptics?

• Tender contract award cycles.
• Hospital antibiogram policies and antisepsis protocols.
• Physician and nursing trust in a product’s consistency (burning sensation, cloudiness, or precipitation risks influence adoption).

What patent litigation affects Ophthochlor and how do settlements shift revenue?

Patent litigation in ophthalmic products affects revenue through:

• Launch delays for authorized generics or full generics.
• Settlement-triggered exclusivity windows.
• Conversion of a disputed claim set into a negotiated launch “carve-out.”

Litigation data required for a financial trajectory

A litigation-driven trajectory needs:

• Case numbers, courts, filing dates, parties.
• Asserted patents and claim constructions.
• Summary judgment and trial dates.
• Final settlement agreements and launch terms.

Open record constraints prevent a defensible case-by-case litigation narrative for Ophthochlor based solely on the name provided.

How does FDA regulatory status influence market timing for Ophthochlor?

Regulatory status changes market dynamics via:

• Time-to-approval for generic entries.
• Label continuity requirements.
• Process validation and comparability constraints that slow copy products.

Key FDA variables that shape entry

• Whether Ophthochlor is covered under an ANDA or 505(b)(2) route for copies.
• Whether the product depends on referenced clinical data.
• Whether manufacturing sites and sterility assurance processes become limiting.

What generic launch scenarios exist for Ophthochlor?

Generic trajectory in ophthalmic antiseptics commonly falls into three scenarios:

1. Early entry: narrow patent coverage or quick regulatory pathway approvals.
2. Staggered entry: copies launch by strength or specific presentation only.
3. Delayed entry: patent thickets, settlements, or formulation barriers hold back launch.

What matters most for the “scenario” determination?

• Breadth of composition/formulation claims.
• Whether the marketed product is within the precise claimed ranges.
• Whether generic applicants can use alternative excipients/pH while keeping bioequivalence and stability.

Geographic coverage: where does Ophthochlor win and where does competition bite?

Ophthochlor’s revenue sensitivity depends on:

• Regulatory approvals by country.
• Patent enforcement strength and speed of local litigation.
• Import tariffs and procurement policy in public tenders.

Typical geography patterns for ophthalmic generics

• Higher generic pressure in markets with rapid tender replacement and mature procurement frameworks.
• Slower erosion in regulated formularies with strict substitution policies.

Financial trajectory: how to model Ophthochlor revenue growth versus erosion

A reliable financial trajectory model needs at minimum:

• Verified annual sales by market and channel.
• Track record of substitution and tender outcomes.
• Exclusivity and patent cliff schedule.

Given the lack of verifiable Ophthochlor product identifiers and patent listings in the supplied prompt, the only defensible statement is a pattern-based trajectory structure used across ophthalmic antiseptics:

Revenue shape under exclusivity and competitive entry

• Launch/adoption phase: growth driven by formulary inclusion, institutional contracts, and clinic stocking.
• Maturation phase: plateau as prescribing stabilizes.
• Erosion phase: decline when multi-source supply enters or tender bidding shifts net pricing down.
• Stabilization: potential rebound if branded promotional intensity increases, if generics are less stable or have supply issues, or if the brand holds specific tender segments.

Key drivers and risks table for Ophthochlor (business decision focus)

Category	Driver	Upside	Downside	What to monitor
Demand	Hospital/procedure antisepsis protocols	Institutional stickiness	Tender churn	Tender award dates, contract renewals
Pricing	Multi-source substitution	Better channel mix	Net price compression	Net price vs list price, rebate changes
Regulatory	Copy pathway speed	Faster generic adoption shifts volumes to category	Regulatory delays	Approval timing for ANDA/505(b)(2) copies
IP	Composition/formulation breadth	Longer exclusivity = reduced erosion	Narrow coverage = rapid entry	Patent expiration schedule, claim scope outcomes
Litigation	Settlements and 30-month stays	Launch locked behind risk	Knock-on delay for copies triggers later erosion	Court orders and settlement terms
Supply	Sterility/stability	Continuity improves procurement	Stockouts lose accounts	Manufacturing site changes, recalls

Key Takeaways

• Ophthochlor’s financial trajectory in ophthalmic antiseptics is governed by exclusivity and patent breadth, not by clinical adoption alone.
• Market erosion risk rises quickly when patents do not cover the specific commercial formulation and when multiple antiseptic alternatives are tender-eligible.
• A litigation and exclusivity-based revenue outlook requires verified FDA listing and patent registry ties to the exact marketed product presentation; without those, a precision revenue model cannot be produced from the information provided.
• The highest leverage monitoring points are tender cycles, net price compression, and any regulatory or patent events that govern first generic or authorized-copy launch timing.

FAQs

1) How quickly do branded ophthalmic antiseptics lose share after first authorized generic entry?
Typically within one to two tender cycles, depending on formulary substitution rules and supply reliability of the multi-source competitors.

2) What patent layers matter most for ophthalmic solution products like Ophthochlor?
Formulation and container-closure claims often matter as much as composition claims when the commercial product is defined by pH, stabilizers, and stability targets.

3) Do Paragraph IV challenges usually produce multi-year revenue protection?
They can, when first-filer procedural posture and court outcomes sustain a stay or settlement-driven launch timing.

4) How do hospital procurement policies affect antiseptic eye drop market dynamics?
They shift demand from physician preference to tender awards, making revenue more sensitive to contract renewal timing and compliance requirements.

5) What competitive signals indicate an imminent price war in ophthalmic antiseptics?
A shift in tender terms favoring lower net price, increased multi-source availability, and discounting tied to authorized suppliers.

---

References

No sources were cited because Ophthochlor-specific product identifiers, FDA listing status, and patent registry records were not provided in the prompt content.